Cargando…

Alzheimer's disease drug development pipeline: 2019

INTRODUCTION: Alzheimer's disease (AD) has few available treatments, and there is a high rate of failure in AD drug development programs. Study of the AD drug development pipeline can provide insight into the evolution of drug development and how best to optimize development practices. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cummings, Jeffrey, Lee, Garam, Ritter, Aaron, Sabbagh, Marwan, Zhong, Kate
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Featured Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617248/ https://www.ncbi.nlm.nih.gov/pubmed/31334330 http://dx.doi.org/10.1016/j.trci.2019.05.008

Ejemplares similares

Alzheimer's disease drug development pipeline: 2018
por: Cummings, Jeffrey, et al.
Publicado: (2018)

Alzheimer's disease drug development pipeline: 2020
por: Cummings, Jeffrey, et al.
Publicado: (2020)

Alzheimer's drug-development pipeline: 2016
por: Cummings, Jeffrey, et al.
Publicado: (2016)

Alzheimer's disease drug development pipeline: 2017
por: Cummings, Jeffrey, et al.
Publicado: (2017)

Alzheimer's disease drug development pipeline: 2021
por: Cummings, Jeffrey, et al.
Publicado: (2021)

Alzheimer's disease drug development pipeline: 2023
por: Cummings, Jeffrey, et al.
Publicado: (2023)

Alzheimer's disease drug development pipeline: 2022
por: Cummings, Jeffrey, et al.
Publicado: (2022)

Repurposed agents in the Alzheimer’s disease drug development pipeline
por: Bauzon, Justin, et al.
Publicado: (2020)

Correction: Repurposed agents in the Alzheimer’s disease drug development pipeline
por: Bauzon, Justin, et al.
Publicado: (2023)

Alzheimer’s disease drug-development pipeline: few candidates, frequent failures
por: Cummings, Jeffrey L, et al.
Publicado: (2014)

Alzheimer’s Disease Drug Development Pipeline 2020
por: Sabbagh, M.N.
Publicado: (2020)

Who funds Alzheimer's disease drug development?
por: Cummings, Jeffrey, et al.
Publicado: (2021)

The costs of developing treatments for Alzheimer's disease: A retrospective exploration
por: Cummings, Jeffrey L., et al.
Publicado: (2021)

Clinical Trials for Disease-Modifying Therapies in Alzheimer’s Disease: A Primer, Lessons Learned, and a Blueprint for the Future(1)
por: Cummings, Jeffrey, et al.
Publicado: (2018)

Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology
por: Sabbagh, Marwan, et al.
Publicado: (2011)

Accelerating drug development for Alzheimer's disease through the use of data standards
por: Neville, Jon, et al.
Publicado: (2017)

Development of Written Materials for Participants in an Alzheimer's Disease and Related Dementias Screening Trial
por: Head, Katharine J, et al.
Publicado: (2022)

Enrichment factors for clinical trials in mild-to-moderate Alzheimer's disease
por: Ballard, Clive, et al.
Publicado: (2019)

The effect of statins on rate of cognitive decline in mild cognitive impairment
por: Smith, Kyle B., et al.
Publicado: (2017)

Tolerability of ORM-12741 and effects on episodic memory in patients with Alzheimer's disease
por: Rinne, Juha O., et al.
Publicado: (2016)

Brain structures and networks responsible for stimulation‐induced memory flashbacks during forniceal deep brain stimulation for Alzheimer's disease
por: Germann, Jürgen, et al.
Publicado: (2021)

Randomized, controlled, proof-of-concept trial of MK-7622 in Alzheimer's disease
por: Voss, Tiffini, et al.
Publicado: (2018)

MCLENA-1: A Phase II Clinical Trial for the Assessment of Safety, Tolerability, and Efficacy of Lenalidomide in Patients with Mild Cognitive Impairment Due to Alzheimer’s Disease
por: Decourt, Boris, et al.
Publicado: (2020)

Open Peer Commentary to “Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE Trials as reported by Biogen December 2019”
por: Sabbagh, Marwan Noel, et al.
Publicado: (2020)

Fluid Biomarkers in Clinical Trials of Alzheimer’s Disease Therapeutics
por: Ritter, Aaron, et al.
Publicado: (2015)

Refreshing the biologic pipeline 2020
por: Hodgson, John
Publicado: (2021)

Erratum: Alzheimer's disease drug development pipeline: 2023
Publicado: (2023)

FDA position statement “Early Alzheimer's disease: Developing drugs for treatment, Guidance for Industry”
por: Sabbagh, Marwan N., et al.
Publicado: (2019)

A 24-week double-blind placebo-controlled study of the efficacy and safety of the AMPA modulator S47445 in patients with mild to moderate Alzheimer's disease and depressive symptoms
por: Bernard, Katy, et al.
Publicado: (2019)

Multiple deadlocks in the development of nonprofit drugs
por: Cvek, Boris
Publicado: (2022)

Alzheimer's disease Archimedes condition-event simulator: Development and validation
por: Kansal, Anuraag R., et al.
Publicado: (2018)

The Cause of Alzheimer’s Disease: The Theory of Multipathology Convergence to Chronic Neuronal Stress
por: Decourt, Boris, et al.
Publicado: (2022)

Bolstering the pipeline for primary care: a proposal from stakeholders in medical education
por: Shi, Hanyuan, et al.
Publicado: (2016)

Endotype reversal as a novel strategy for screening drugs targeting familial Alzheimer's disease
por: Caldwell, Andrew B., et al.
Publicado: (2022)

The Power of Two:: One Academic-Practice Partnership’s Response to Coronavirus Disease 2019 (COVID-19)
por: Reynolds, Staci, et al.
Publicado: (2021)

Novel drug candidates targeting Alzheimer’s disease: ethical challenges with identifying the relevant patient population
por: Gustavsson, Erik, et al.
Publicado: (2021)

Effects of traumatic brain injury and posttraumatic stress disorder on development of Alzheimer's disease in Vietnam Veterans using the Alzheimer's Disease Neuroimaging Initiative: Preliminary report
por: Weiner, Michael W., et al.
Publicado: (2017)

Neuroscience learning from longitudinal cohort studies of Alzheimer's disease: Lessons for disease-modifying drug programs and an introduction to the Center for Neurodegeneration and Translational Neuroscience
por: Ritter, Aaron, et al.
Publicado: (2018)

Midlife anticholinergic drug use, risk of Alzheimer's disease, and brain atrophy in community-dwelling older adults
por: Chuang, Yi-Fang, et al.
Publicado: (2017)

Fresh from the biotech pipeline: too much, too fast?
por: Senior, Melanie
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tfu33upg92omhd9vnre8e22vpv